EQS-News: ADC Therapeutics Presents Pre-Clinical Data for Two Investigational ADCs at the American Association for Cancer Research Annual Meeting

Nachricht vom 30.03.2017 (www.4investors.de) -


EQS Group-News: ADC Therapeutics SA / Schlagwort(e): Wissenschaftl. Publikation

ADC Therapeutics Presents Pre-Clinical Data for Two Investigational ADCs at the American Association for Cancer Research Annual Meeting
30.03.2017 / 10:39
ADC Therapeutics Presents Pre-Clinical Data for Two Investigational ADCs at the American Association for Cancer Research Annual Meeting

Lausanne, Switzerland, March 30, 2017 - ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2017 taking place April 1-5, 2017 in Washington, D.C., USA. The two poster presentations will highlight strong preclinical results from its investigational ADC portfolio including ADCT-402 and ADCT-502.


Poster titles and highlights of the data that will be presented are:

Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing Antibody Drug Conjugate (ADC) targeting HER2-expressing solid tumorsAbstract #52, April 2, 1:00 pm - 5:00 pm ET
 

- ADCT-502 is an ADC composed of an engineered version of trastuzumab, directed against human HER2, conjugated to the PBD-based linker-drug tesirine.

- The preclinical data show superior in vivo anti-tumor activity of ADCT-502 compared to T-DM1 in various tumor xenografts with low HER2 levels and support the development of ADCT-502 not only in patients that have become resistant/refractory to T-DM1, but also in patients whose tumors express low levels of HER2, and are not eligible for treatment with T-DM1.

- ADCT anticipates starting a Phase I clinical trial in patients with solid tumors during first half of 2017.


Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing Antibody Drug Conjugate (ADC) targeting CD19-expressing hematological malignanciesAbstract #51, April 2, 2017 1:00 pm - 5:00 pm ET
 

- ADCT-402, currently in Phase I clinical trials for B-cell hematological malignancies, is an ADC composed of a humanized antibody against human CD19, conjugated to the PBD-based linker-drug tesirine.

- The data confirm the mode of action of ADCT-402 and provide relevant pharmacodynamic assays and preclinical safety assessment to guide the clinical development of this ADC in B-cell malignancies.


"We are thrilled by our data being presented at the AACR Annual Meeting which demonstrate both safety and efficacy of our proprietary ADC programs and support our ongoing preclinical and clinical development activities," said Dr. Chris Martin, CEO of ADC Therapeutics. "We look forward to further developing our ADC pipeline for the treatment of both solid and hematological cancers."

About ADCT-402
ADCT-402 is an investigational antibody drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human CD19, conjugated to the PBD-based linker-drug tesirine. Once bound to a CD19-expressing cell, ADCT-402 is internalized into the cell where enzymes release the PBD-based warhead. The PBD-based warhead has the ability to form highly cytotoxic DNA interstrand cross-links, blocking cell division and resulting in cell death. CD19 is a clinically validated target for the treatment of certain CD19-expressing B-cell malignancies. ADCT-402 is being evaluated in two ongoing Phase Ia/Ib clinical trials in patients with relapsed or refractory B-cell lineage non-Hodgkin lymphoma and relapsed or refractory B-cell lineage acute lymphoblastic leukemia.

About ADCT-502
ADCT-502 is an investigational antibody drug conjugate (ADC) composed of the humanized monoclonal antibody trastuzumab directed against the human epidermal growth factor receptor 2 (HER2). The antibody is site-specifically conjugated to the PBD-based linker-drug tesirine. Once bound to the HER2 receptor on the cell surface, ADCT-502 is internalized into the cell where enzymes release the PBD-based warhead. HER2 is a well-established, clinically validated target expressed in a wide variety of solid tumors, including breast, gastric, esophageal, bladder and lung cancer. ADCT anticipates starting a Phase I clinical trial in patients with solid tumors during first half of 2017.

About ADC Therapeutics
Founded in 2012, ADC Therapeutics SA (ADCT) is an oncology drug development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major types of hematological malignancies and solid tumors. The Company's ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads via a chemical linker. Its three lead programs, ADCT-301, ADCT-402, and ADCT-502 are in five Phase I clinical trials in the USA and in Europe. ADCT enjoys strong relationships with world class partners, including Astrazeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne, Switzerland and has operations in London, San Francisco and New Jersey (www.adctherapeutics.com).

For more information please contact:
Dr. Chris Martin
Chief Executive Officer
chris.martin@adctherapeutics.com
Tel.: +41 (0) 21 653 0200

Alexandre Müller
Dynamics Group
amu@dynamicsgroup.ch
Tel: +41 (0) 43 268 3231


Zusatzmaterial zur Meldung:Dokument: http://n.eqs.com/c/fncls.ssp?u=NQWLPECEWKDokumenttitel: ADCR_AACR_30.3.2017
Ende der Medienmitteilung



560033  30.03.2017 





PfeilbuttonQSC will an der Börse und bei Kunden in die Offensive - Exklusiv-Interview
PfeilbuttonSTARAMBA SE: „Das Potenzial für STARAMBA.spaces ist riesig“ - Exklusiv-Interview
PfeilbuttonAnleihe-Emission von Euges: „Wollen eine Vertrauensgrundlage aufbauen“ - Exklusiv-Interview!
PfeilbuttonBitcoins, Tulpen und die Lust auf schnelles Geld
PfeilbuttonNanogate: „Nächster Wachstumssprung“ - Exklusiv-Interview mit Ralf Zastrau


+++ Exklusive Interviews und Analysen - gratis in Ihre Mailbox! +++

Tragen Sie sich jetzt für unseren kostenlosen 4investors Newsletter ein.


Bestätigungslink nicht per Mail bekommen? Bitte kontrollieren Sie Ihren Spamordner!

Der 4investors Newsletter erscheint unregelmäßig, i.d.R. 2 bis 6 Mal pro Monat. Wir geben ihre Mailadresse an keinen Dritten weiter! Sie können den kostenlosen 4investors Newsletter jederzeit problemlos wieder abbestellen.
comments powered by Disqus


Aktuelle Nachrichten aus der 4investors-Redaktion

15.12.2017 - co.don: Konzernchef Hessel geht
15.12.2017 - Steinhoff versilbert PSG-Anteile - Aktie fällt
15.12.2017 - innogy Aktie: So unterschiedlich können Reaktionen ausfallen
15.12.2017 - CropEnergies: Aktie der Südzucker-Tochter unter Druck - Quartalszahlen
15.12.2017 - mic AG: Kapitalerhöhung über Börsenkurs!
15.12.2017 - Siemens verstärkt Aktivitäten im Bereich Digitalisierung
15.12.2017 - Hönle erreicht die Prognosen
15.12.2017 - Steinhoff Aktie - abseits aller News: Darauf müssen Trader achten!
15.12.2017 - mic Aktie: Der Aufwärtstrend bleibt intakt
15.12.2017 - Nordex Aktie: Gut aufpassen!


Chartanalysen

15.12.2017 - Steinhoff Aktie - abseits aller News: Darauf müssen Trader achten!
15.12.2017 - mic Aktie: Der Aufwärtstrend bleibt intakt
14.12.2017 - Aurelius Aktie: Die Trendentscheidung naht!
14.12.2017 - Dialog Semiconductor Aktie: Hartes Ringen um den Trend
14.12.2017 - Nordex Aktie: Steht hier der Ausbruch nach oben an?
14.12.2017 - Aixtron Aktie: Die Chancen steigen!
14.12.2017 - Softing Aktie: Starkes Kaufsignal voraus?
13.12.2017 - Commerzbank Aktie: Wird das doch noch eine Zitterpartie?
12.12.2017 - Tesla Aktie: Die große Chance?
12.12.2017 - Evotec Aktie: Richtig starke Signale für die Bullen!


Analystenschätzungen

15.12.2017 - SFC Energy: Kursziel für die Aktie massiv erhöht!
15.12.2017 - Aurubis: Neue Analystenstimmen zur Aktie
15.12.2017 - Commerzbank Aktie: Trotz Verkaufsempfehlung Ausbruch bestätigt
15.12.2017 - Wirecard Aktie: Immer noch Aufwärtspotenzial
15.12.2017 - Deutsche Bank Aktie: Neues Kursziel!
15.12.2017 - Hapag-Lloyd: Rating-Ausblick erhöht
14.12.2017 - RWE Aktie: Übertriebene Verluste nach der innogy-Gewinnwarnung?
14.12.2017 - Siemens: Top-Aktie für das kommende Jahr?
14.12.2017 - mutares Aktie: Positive Neuigkeiten
14.12.2017 - Aixtron: Profitiert der Konzern von Apple und Finisar?


Kolumnen

15.12.2017 - EZB gibt sich skeptisch hinsichtlich eines „selbsttragenden Preisauftriebs” - Commerzbank Kolumne
15.12.2017 - Volkswagen Aktie: Top-Bildung möglich - UBS Kolumne
15.12.2017 - DAX: Hohe Volatilität vor Verfallstag - UBS Kolumne
14.12.2017 - Mario Draghi zeigt sich entspannt - VP Bank Kolumne
14.12.2017 - US-Steuerreform: Impulse für mehr Wachstum in 2018 - Nord LB Kolumne
14.12.2017 - Konflikte um den geldpolitischen Kurs in Europa dürften sich weiter verschärfen - National-Bank
14.12.2017 - Fed strafft weiter, weitere Anhebungen im kommenden Jahr wahrscheinlich - Commerzbank Kolumne
14.12.2017 - Siemens Aktie: Bodenbildung möglich - UBS Kolumne
14.12.2017 - DAX: Spannung nach der Zinsentscheidung der Fed - UBS Kolumne
14.12.2017 - Janet Yellen schmeißt zum Abschied noch eine letzte Runde - VP Bank Kolumne

Werbung

All Right Reserved by minimalthemes - ©2014 Stoffels & Barck GbR